Evidence network for deaths_(OS)

1EAGLE (D vs ICC), 20191CheckMate 141, 20162KEYNOTE-040 (all population), 2018 KEYNOTE-040 (CPS >1), 20183KEYNOTE-048 (P vs C ; all population), 2019 KEYNOTE-048 (P vs C ; CPS > 20), 2019 KEYNOTE-048 (P vs C ; CPS > 1), 20191JAVELIN Head and Neck 100, 20211EAGLE (DT vs ICC), 20191CONDOR (DT vs D ; PDL1 TC<25%), 20191CONDOR (DT vs T ; PDL1 TC<25%), 20193KEYNOTE-048 (PC vs C ; all population), 2019 KEYNOTE-048 (PC vs C ; CPS > 1), 2019 KEYNOTE-048 (PC vs C ; CPS > 20), 2019Standard of Care (SoC)cetuximab plus platin plus 5FUplacebodurvalumab alonetremelimumabnivolumab alonepembrolizumab aloneavelumab alonedurvalumab plus tremelimumabpembrolizumab plus 5FU plus platindirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)cetuximab plus platin plus 5FUplacebodurvalumab alonetremelimumabnivolumab alonepembrolizumab aloneavelumab alonedurvalumab plus tremelimumabpembrolizumab plus 5FU plus platin
Standard of Care (SoC)---NANANANANANANANANA
cetuximab plus platin plus 5FUNA---NANANANANANANANA
placeboNANA---NANANANANANANA
durvalumab aloneNANANA---NANANANANANA
tremelimumabNANANANA---NANANANANA
nivolumab aloneNANANANANA---NANANANA
pembrolizumab aloneNANANANANANA---NANANA
avelumab aloneNANANANANANANA---NANA
durvalumab plus tremelimumabNANANANANANANANA---NA
pembrolizumab plus 5FU plus platinNANANANANANANANANA---

pathologies: 6,275,106,104,105,276,103,277,102,109,278,101,192,114 - treatments: 875 result logic